Kezar Life Sciences Management
Management criteria checks 1/4
Kezar Life Sciences' CEO is Chris Kirk, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is $2.60M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $355.65K. The average tenure of the management team and the board of directors is 2 years and 7 years respectively.
Key information
Chris Kirk
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 9.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | 2yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08
FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21
Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$242k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$88m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$2m | US$468k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$64m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$2m | US$443k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$45m |
| Dec 31 2020 | US$880k | US$426k | -US$42m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$2m | US$410k | -US$35m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$962k | US$365k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$745k | US$325k | -US$9m |
Compensation vs Market: Chris's total compensation ($USD2.60M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Kirk (51 yo)
less than a year
Tenure
US$2,602,155
Compensation
Dr. Christopher J. Kirk, also known as Chris, Ph.D. serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) He is a Co-Founder of Kezar Life Sciences,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$2.60m | 0.59% $ 355.6k | |
| Co-Founder & Director | no data | US$4.83m | 0.60% $ 359.6k | |
| CFO & Secretary | 6.2yrs | US$2.01m | 0.026% $ 15.4k | |
| Chief Business Officer & Head of Strategy | 1.8yrs | US$1.76m | 0% $ 0 | |
| Co-Founder | no data | no data | no data | |
| Vice President of Investor Relations & External Affairs | no data | no data | no data | |
| Chief Legal Officer | 5.1yrs | no data | 0.013% $ 8.0k | |
| Senior Vice President of Research & Drug Discovery | 2.1yrs | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| VP & Corporate Controller | no data | no data | no data |
2.0yrs
Average Tenure
51yo
Average Age
Experienced Management: KZR's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$2.60m | 0.59% $ 355.6k | |
| Co-Founder & Director | 9.3yrs | US$4.83m | 0.60% $ 359.6k | |
| Independent Director | 7.4yrs | US$155.34k | 0.087% $ 52.5k | |
| Independent Director | 8.3yrs | US$141.22k | 1.22% $ 734.4k | |
| Independent Chairman | 6.6yrs | US$194.56k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$149.45k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$164.59k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$161.58k | 0% $ 0 |
7.0yrs
Average Tenure
54yo
Average Age
Experienced Board: KZR's board of directors are considered experienced (7 years average tenure).